Skip to main content

BioticsAI

Category: AI in Healthcare

An AI-powered clinical intelligence platform designed to assist clinicians in detecting fetal abnormalities and automating ultrasound reporting in real-time. BioticsAI was founded in 2020. The company is led by Robhy Bustami. Based in San Francisco, USA. Team size: 11-50. Total funding raised: $2.52M. Latest round: Seed. Key investors include ["Blackbird Ventures","Techstars","StartUp Health","Pioneer Fund"].

Founded
2020
Headquarters
San Francisco, USA
Team size
11-50
Total funding
$2.52M

Value proposition

Reduces the high rate of fetal misdiagnosis (currently ~50%) by providing real-time diagnostic support and automates the reporting process to save clinicians up to 15 minutes per scan.

Products and solutions

["Real-time Fetal Abnormality Detection Engine","Automated Ultrasound Reporting & Documentation System","Quality Assurance (QA) Dashboard for clinical oversight","Cloud-based Image Management and Archiving Platform"]

Unique value

Unlike traditional post-scan analysis tools, BioticsAI operates in real-time during the procedure, acting as a 'second pair of eyes' to ensure all required anatomical views are captured correctly and screened for malformations.

Target customer

Obstetricians, maternal-fetal medicine (MFM) specialists, sonographers, radiology departments, and health systems/hospitals.

Industries served

["Healthcare","Medical Imaging","Obstetrics & Gynecology","HealthTech / MedTech"]

Technology advantage

Hardware-agnostic software integration that works with existing ultrasound machines; utilizes proprietary computer vision models trained on diverse clinical datasets to overcome variability in fetal positioning and image quality.

How they differentiate

Hardware-agnostic AI that provides real-time screening for over 50 fetal malformations and automates clinical reporting, whereas many competitors focus primarily on automated biometry (measurements) or specific hardware integrations.

Main competitors

["Sonio (acquired by Samsung)","Intelligent Ultrasound","GE Healthcare (SonoLyst)"]

Key partnerships

["Techstars (Accelerator partner)","StartUp Health (Global health innovation partner)","Alexandria University (Clinical validation and research partner)","Blackbird Ventures and Pioneer Fund (Strategic investment partners)"]

Notable customers

["Alexandria University (Clinical Partner)","Techstars Healthcare Accelerator"]

Major milestones

["Selected for Techstars Healthcare Accelerator in 2022","Winner of TechCrunch Disrupt Startup Battlefield 2023 ($100,000 equity-free prize)","Gained FDA approval for its AI-powered fetal ultrasound product in January 2026"]

Growth metrics

Winner of TechCrunch Disrupt Startup Battlefield 2023; transitioned from accelerator stage to FDA-cleared commercial stage.

Market positioning

Specialized clinical intelligence challenger in the maternal-fetal medicine (MFM) and prenatal diagnostics space.

Geographic focus

North America (primary regulatory focus) and the Middle East (clinical validation and research roots).

Patents and IP

Proprietary AI algorithms and computer vision architectures; specific patent filings relate to automated fetal anatomy identification and diagnostic workflows (IP details typically held as trade secrets or pending during early commercialization).

About Robhy Bustami

Robhy Bustami is an AI architect and engineer with over 8 years of experience in enterprise technology and cloud solutions. Prior to founding BioticsAI, he served as a Watson AI Platform and Red Hat Solutions Architect at IBM, where he specialized in architecting AI solutions for enterprise clients. He also held a Solutions Architect role at Nimbl. His motivation for BioticsAI stems from a family background in obstetrics, combining clinical insights with his expertise in computer vision and machine learning.

Official website: